Plain-English translation of NCT05985330 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a pilot study testing whether measuring nitric oxide in your breath can predict how well anti-PD-L1 immunotherapy will work for your advanced lung cancer. Immunotherapy is a powerful cancer treatment that helps your immune system fight cancer cells, but it doesn't work equally well for everyone. Researchers want to see if this simple breath test might help identify which patients are most likely to benefit from this medication.
Currently, doctors cannot reliably predict which patients will respond well to immunotherapy before treatment starts. By studying nitric oxide levels in breath, researchers hope to find an early warning sign that could help personalize treatment and improve outcomes for lung cancer patients.
You likely qualify if…
You likely don't qualify if…
You will visit the hospital twice: once before your first immunotherapy treatment and once after your fourth dose. At each visit, you will perform a simple breath test that measures nitric oxide in your breath — similar to a breathing exercise you might do at a routine doctor's visit. The study will track how well the immunotherapy works for you over time and compare those results to your breath test measurements.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
France